Trulieve Reports Third Quarter 2026 Results

Trulieve reported Q3 2026 revenue of $230 million, down 20% year over year, with a 64% gross margin and $89 million in adjusted EBITDA (39% margin); GAAP net income attributable to common shareholders was $1 million. Operating cash flow was $74 million and free cash flow was $45 million for the quarter, while cash totaled $327 million. The company received final DEA registrations for state-licensed medical marijuana dispensaries and repaid $65 million of mortgage notes ahead of their 2028 maturity; results reflect medical operations only after Harvest was deconsolidated.

Analysis

Scope reset matters more than the headline numbers: Q3 contains only Trulieve Cannabis Corp.’s medical operations, while prior periods include Harvest mixed-use results. Treat reported revenue comparisons as non-comparable until the 10-Q provides a clean pro forma baseline; the apparent sequential decline is not a reliable demand signal. The more useful read-through is that the smaller reported business still generated a 64% gross margin, but near-zero GAAP earnings and $45m Q3 free cash flow temper the adjusted EBITDA narrative. Cash conversion deserves scrutiny: operating cash flow included a $27m increase in uncertain tax position liabilities, so reported cash generation benefited from a tax-liability movement that should not be assumed to recur.

DEA registrations and potential 280E relief could create a meaningful structural cash-flow tailwind, but timing, tax treatment and the large $625m uncertain-tax-position liability are pivotal. The benefit may be shared across eligible operators, limiting durable relative advantage; the near-term edge may accrue to scaled firms able to deploy cash into licensing, brands and market expansion. Conversely, continued retail concentration leaves Trulieve exposed to local price competition. Georgia traffic growth is an early indicator, not yet proof of durable revenue or margin uplift.

Near term, expect headline-driven volatility and a possible sector sympathy move. Over 1–3 months, the 10-Q’s tax disclosures and evidence of a comparable revenue run-rate are the key catalysts. Over 6–18 months, realized cash-tax savings and state-market execution matter more than announced capacity. Reversal risks include delayed or challenged implementation, weaker pricing, and tax liabilities that do not unwind as expected. The contrarian point: investors may over-credit immediate tax relief while underweighting cash-flow quality and the non-comparable earnings base.

Key Decisions for Investors

• No chase on the earnings release alone. Put Trulieve Cannabis Corp. on a catalyst watchlist; consider an incremental long only after the 10-Q clarifies the pro forma operating baseline and confirms cash-tax savings, with position risk anchored to subsequent FCF rather than adjusted EBITDA.
• For the next 1–3 months, monitor DEA/280E implementation details, tax-liability roll-forward, and management’s quantified tax outlook. Treat any claimed benefit as unverified until reflected in cash taxes or a clearly supported liability release.
• If taking sector exposure, prefer a diversified U.S. cannabis-operator basket over a single-name bet until evidence shows Trulieve’s Georgia and Texas expansion converts traffic and licensing into sustained same-store sales and margins; broad regulatory relief may benefit peers such as Curaleaf, Green Thumb Industries, Verano and Cresco as well.
• Thesis failure signals: no measurable reduction in cash taxes, rising uncertain tax liabilities, or further deterioration in comparable sales/gross margin once a clean baseline is available. Reassess if normalized quarterly free cash flow weakens materially after separating tax-liability movements.